Gene therapy in epilepsy - Is it time for clinical trials?

Nature Reviews Neurology

Volumn 10, Issue 5, 2014, Pages 300-304

  Kullmann, Dimitri M ^a   Schorge, Stephanie ^a   Walker, Matthew C ^a   Wykes, Robert C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BIOLOGICAL MARKER; GROWTH FACTOR; LENTIVIRUS VECTOR; TRANSCRIPTION FACTOR; 4 AMINOBUTYRIC ACID A RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; FIBROBLAST GROWTH FACTOR 2; GALANIN; HALORHODOPSIN; HERPESVIRUS VECTOR; MICRORNA; MICRORNA 134; NEURON RESTRICTIVE SILENCING TRANSCRIPTION FACTOR; NEUROPEPTIDE Y; PARVOVIRUS VECTOR; SHORT HAIRPIN RNA; TETANUS TOXIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

BRAIN REGION; CLINICAL EFFECTIVENESS; DISEASE MODEL; DISEASE SEVERITY; DNA MODIFICATION; ELECTROENCEPHALOGRAPHY; EPILEPSY; EPILEPTIC DISCHARGE; EPILEPTOGENESIS; EXPERIMENTAL ANIMAL; GENE TARGETING; GENE THERAPY; GENETIC ASSOCIATION; GENETIC MANIPULATION; HERPES SIMPLEX VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; REVIEW; RISK ASSESSMENT; RNA INTERFERENCE; TEMPORAL LOBE EPILEPSY; THERAPY EFFECT; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SENSITIVITY; ELECTROENCEPHALOGRAM; ENCEPHALITIS; EPILEPTIC STATE; FOCAL EPILEPSY; GENE DELIVERY SYSTEM; GENE EXPRESSION; IMMUNE RESPONSE; LONG TERM CARE; MESIAL TEMPORAL LOBE EPILEPSY; MORBIDITY; MORTALITY; MUTAGENESIS; NERVE CELL EXCITABILITY; OPTOGENETICS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHARMACORESISTANCE; RISK FACTOR; SEIZURE; SIGNAL TRANSDUCTION; TEMPORAL LOBECTOMY; TRAUMATIC BRAIN INJURY; UPREGULATION;

CLINICAL TRIALS AS TOPIC; EPILEPSY; GENETIC THERAPY; HUMANS;

EID: 84900844114     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.43     Document Type: Review

References (60)

1. Picot, M. C., Baldy-Moulinier, M., Daurès, J. P., Dujols, P. & Crespel, A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: A population-based study in a Western European country. Epilepsia 49, 1230-1238 (2008
2. Kwan, P., Schachter, S. C. & Brodie, M. J. Drug-resistant epilepsy. N. Engl. J. Med. 365, 919-926 (2011
3. Schuele, S. U. & Lüders, H. O. Intractable epilepsy: Management and therapeutic alternatives. Lancet Neurol. 7, 514-524 (2008
4. Kahane, P. & Depaulis, A. Deep brain stimulation in epilepsy: What is next?. Curr. Opin. Neurol. 23, 177-182 (2010
5. Van Dycke, A., Raedt, R., Vonck, K. & Boon, P. Local delivery strategies in epilepsy: A focus on adenosine. Seizure 20, 376-382 (2011
6. Rothman, S. M. The therapeutic potential of focal cooling for neocortical epilepsy. Neurotherapeutics 6, 251-257 (2009
7. Sebe, J. Y. & Baraban, S. C. The promise of an interneuron-based cell therapy for epilepsy. Dev. Neurobiol. 71, 107-117 (2011
8. Simonato, M. et al. Progress in gene therapy for neurological disorders. Nat. Rev. Neurol. 9, 277-291 (2013
9. Richichi, C. et al. Anticonvulsant and antiepileptogenic effects mediated by adeno-Associated virus vector neuropeptide Y expression in the rat hippocampus. J. Neurosci. 24, 3051-3059 (2004
10. Noè, F. et al. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 131, 1506-1515 (2008
11. Paradiso, B. et al. Localized delivery of fibroblast growth factor 2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc. Natl Acad. Sci. USA 106, 7191-7196 (2009
12. Haberman, R. P., Samulski, R. J. & McCown, T. J. Attenuation of seizures and neuronal death by adeno-Associated virus vector galanin expression and secretion. Nat. Med. 9, 1076-1080 (2003
13. McCown, T. J. Adeno-Associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo. Mol. Ther. 14, 63-68 (2006
14. Wykes, R. C. et al. Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. Sci. Transl. Med. 4, 161ra152 (2012
15. Kanter-Schlifke, I., Georgievska, B., Kirik, D. & Kokaia, M. Seizure suppression by GDNF gene therapy in animal models of epilepsy. Mol. Ther. 15, 1106-1113 (2007
16. Woldbye, D. P. D. et al. Adeno-Associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. Brain 133, 2778-2788 (2010
17. Paradiso, B. et al. Localized overexpression of FGF 2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus. Epilepsia 52, 572-578 (2011
18. Bovolenta, R. et al. Hippocampal FGF 2 and BDNF overexpression attenuates epileptogenesis-Associated neuroinflammation and reduces spontaneous recurrent seizures. J. Neuroinflammation 7, 81 (2010
19. Raol, Y. H. et al. Enhancing GABAA receptor a1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. J. Neurosci. 26, 11342-11346 (2006
20. McClelland, S. et al. Neuron-restrictive silencer factor-mediated hyperpolarization-Activated cyclic nucleotide gated channelopathy in experimental temporal lobe epilepsy. Ann. Neurol. 70, 454-464 (2011
21. Jimenez-Mateos, E. M. et al. Silencing microRNA 134 produces neuroprotective and prolonged seizure-suppressive effects. Nat. Med. 18, 1087-1094 (2012
22. Annegers, J. F., Hauser, W. A., Coan, S. P. & Rocca, W. A. A population-based study of seizures after traumatic brain injuries. N. Engl. J. Med. 338, 20-24 (1998
23. Annegers, J. F., Hauser, W. A., Beghi, E., Nicolosi, A. & Kurland, L. T. The risk of unprovoked seizures after encephalitis and meningitis. Neurology 38, 1407-1410 (1988
24. Burn, J. et al. Epileptic seizures after a first stroke: The Oxfordshire Community Stroke Project. BMJ 315, 1582-1587 (1997
25. Galanopoulou, A. S. et al. Identification of new epilepsy treatments: Issues in preclinical methodology. Epilepsia 53, 571-582 (2012
26. Wilcox, K. S. et al. Issues related to development of new antiseizure treatments. Epilepsia 54 (Suppl. 4), 24-34 (2013
27. Bien, C. G. et al. Trends in presurgical evaluation and surgical treatment of epilepsy at one centre from 1988-2009. J. Neurol. Neurosurg. Psychiatr. 84, 54-61 (2013
28. De Tisi, J. et al. The long-Term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: A cohort study. Lancet 378, 1388-1395 (2011
29. Hermann, B. P., Wyler, A. R., Bush, A. J. & Tabatabai, F. R. Differential effects of left and right anterior temporal lobectomy on verbal learning and memory performance. Epilepsia 33, 289-297 (1992
30. Kelly, K. M. et al. Photothrombotic brain infarction results in seizure activity in aging Fischer 344 and Sprague Dawley rats. Epilepsy Res. 47, 189-203 (2001
31. Kharlamov, E. A., Jukkola, P. I., Schmitt, K. L. & Kelly, K. M. Electrobehavioral characteristics of epileptic rats following photothrombotic brain infarction. Epilepsy Res. 56, 185-203 (2003
32. Paz, J. T. et al. Closed-loop optogenetic control of thalamus as a tool for interrupting seizures after cortical injury. Nat. Neurosci. 16, 64-70 (2013
33. Whittington, M. A. & Jefferys, J. G. Epileptic activity outlasts disinhibition after intrahippocampal tetanus toxin in the rat. J. Physiol. (Lond.) 481, 593-604 (1994
34. Mellanby, J., George, G., Robinson, A. & Thompson, P. Epileptiform syndrome in rats produced by injecting tetanus toxin into the hippocampus. J. Neurol. Neurosurg. Psychiatr. 40, 404-414 (1977
35. Nilsen, K. E., Walker, M. C. & Cock, H. R. Characterization of the tetanus toxin model of refractory focal neocortical epilepsy in the rat. Epilepsia 46, 179-187 (2005
36. Louis, E. D., Williamson, P. D. & Darcey, T. M. Chronic focal epilepsy induced by microinjection of tetanus toxin into the cat motor cortex. Electroencephalogr. Clin. Neurophysiol. 75, 548-557 (1990
37. Hagemann, G., Hoeller, M., Bruehl, C., Lutzenburg, M. & Witte, O. W. Effects of tetanus toxin on functional inhibition after injection in separate cortical areas in rat. Brain Res. 818, 127-134 (1999
38. Mainardi, M., Pietrasanta, M., Vannini, E., Rossetto, O. & Caleo, M. Tetanus neurotoxin-induced epilepsy in mouse visual cortex. Epilepsia 53, e132-e136 (2012
39. Kullmann, D. M. Neurological channelopathies. Annu. Rev. Neurosci. 33, 151-172 (2010
40. Lin, E. J. D., Young, D., Baer, K., Herzog, H. & During, M. J. Differential actions of NPY on seizure modulation via Y1 and Y2 receptors: Evidence from receptor knockout mice. Epilepsia 47, 773-780 (2006
41. Boison, D. in Jasper's Basic Mechanisms of the Epilepsies (eds Noebels, J. L. et al.) (National Center for Biotechnology Information, 2012).
42. Haberman, R. et al. Therapeutic liabilities of in vivo viral vector tropism: Adeno-Associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity. Mol. Ther. 6, 495-500 (2002
43. Boison, D. Inhibitory RNA in epilepsy: Research tools and therapeutic perspectives. Epilepsia 51, 1659-1668 (2010
44. Mazzuferi, M. et al. Nrf2 defense pathway: Experimental evidence for its protective role in epilepsy. Ann. Neurol. 74, 560-568 (2013
45. Tønnesen, J., Sørensen, A. T., Deisseroth, K., Lundberg, C. & Kokaia, M. Optogenetic control of epileptiform activity. Proc. Natl Acad. Sci. USA 106, 12162-12167 (2009
46. Sukhotinsky, I. et al. Optogenetic delay of status epilepticus onset in an in vivo rodent epilepsy model. PLoS ONE 8, e62013 (2013
47. Krook-Magnuson, E., Armstrong, C., Oijala, M. & Soltesz, I. On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy. Nat. Commun. 4, 1376 (2013
48. Manfredsson, F. P. & Mandel, R. J. Development of gene therapy for neurological disorders. Discov. Med. 9, 204-211 (2010
49. Gray, S. J. et al. Directed evolution of a novel adeno-Associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18, 570-578 (2010
50. Abordo-Adesida, E. et al. Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum. Gene Ther. 16, 741-751 (2005
51. Rodnitzky, R. L. Upcoming treatments in Parkinson's disease, including gene therapy. Parkinsonism Relat. Disord. 18 (Suppl. 1), S37-S40 (2012
52. Rahim, A. A. et al. Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther. 16, 509-520 (2009
53. Bartlett, D. L. et al. Oncolytic viruses as therapeutic cancer vaccines. Mol. Cancer 12, 103 (2013
54. Binnie, C. D. Cognitive impairment during epileptiform discharges: Is it ever justifiable to treat the EEG?. Lancet Neurol. 2, 725-730 (2003
55. Noebels, J. A perfect storm: Converging paths of epilepsy and Alzheimer's dementia intersect in the hippocampal formation. Epilepsia 52 (Suppl. 1), 39-46 (2011
56. Mavilio, F. Gene therapies need new development models. Nature 490, 7 (2012
57. Wilson, J. M. Moving to the clinic with gene therapy through our new journal expansion, human gene therapy clinical development. Hum. Gene Ther. 23, 1029-1030 (2012
58. NGVB National Gene Vector Biorepository [online], https://www.ngvbcc.org/ Home.action (2014)
59. Tremblay, J. P. et al. Translating the genomics revolution: The need for an international gene therapy consortium for monogenic diseases. Mol. Ther. 21, 266-268 (2013
60. Lerchner, W., Corgiat, B., Der Minassian, V., Saunders, R. C. & Richmond, B. J. Injection parameters and virus dependent choice of promoters to improve neuron targeting in the nonhuman primate brain. Gene Ther. http://dx.doi.org/10.1038/gt.2013.75..